Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Rating Increased to Hold at Zacks Research

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts also recently issued reports on LKFT. UBS Group reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th. Raymond James Financial reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Royal Bank Of Canada boosted their target price on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen downgraded Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $36.50.

Lakefront Biotherapeutics American Depositary Shares Trading Up 1.6%

NASDAQ LKFT opened at $28.27 on Monday. The stock’s 50 day moving average is $28.27 and its 200 day moving average is $31.19. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $26.42 and a 12 month high of $37.78. The stock has a market cap of $1.86 billion, a PE ratio of -20.05 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The firm had revenue of $1.06 billion during the quarter. On average, analysts forecast that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Lakefront Biotherapeutics American Depositary Shares

Several hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its position in Lakefront Biotherapeutics American Depositary Shares by 2.1% in the 3rd quarter. Bank of America Corp DE now owns 30,949 shares of the biotechnology company’s stock valued at $1,072,000 after acquiring an additional 643 shares during the last quarter. Van ECK Associates Corp grew its position in Lakefront Biotherapeutics American Depositary Shares by 61.6% in the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares during the last quarter. Two Sigma Investments LP grew its position in Lakefront Biotherapeutics American Depositary Shares by 3.7% in the 3rd quarter. Two Sigma Investments LP now owns 22,459 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 800 shares during the last quarter. State of Wyoming bought a new position in Lakefront Biotherapeutics American Depositary Shares in the 2nd quarter valued at $28,000. Finally, Arax Advisory Partners grew its position in Lakefront Biotherapeutics American Depositary Shares by 319.2% in the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,778 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.